Already today, pharmaceuticals, biotechnology and medical technology are the country’s largest export products after paper, and if this trend continues, we can look forward to even greater exports and more skilled jobs. But international competition is fierce. What does it take for Sweden to get the follow-up investments and become a long-term manufacturing country for the world’s life science products?
Wednesday, July 6, 10 – 11 am
Atrium, Volters gränd 8, Visby.
The seminar will address issues such as:
- Where will the world’s medicines be produced in 10 years?
- How does investment in manufacturing relate to investment in research and development?
- Are the recent new investments a temporary upswing or has the trend reversed?
Speakers
Oscar Stenström, State Secretary to the Minister for Trade Ann Linde
The Government’s reindustrialization strategy will help to strengthen industry’s international competitiveness and make investments in Swedish industry more attractive. During the seminar, he will discuss with industry representatives how the initiative will attract life science manufacturing to Sweden.
Jan Erneberg, General Manager at GE Healthcare Global Supply Chain
With an investment of SEK 870 million, GE Healthcare will double its manufacturing capacity in Uppsala over the next three years. Listen to Jan Erneberg talk about the considerations for the decision to locate the investment in Sweden and the plans for the future.
Margareta Ozolins, VP Sweden Operations and Head of AstraZeneca’s factoriesin Södertälje
Södertälje is AstraZeneca’s largest manufacturing site and in the coming years the company is investing over SEK 2 billion in an additional facility. Margareta Ozolins talks about the global trends affecting where future pharmaceutical production will take place and what role AstraZeneca sees Sweden playing.
Kirsti Gjellan, Head of Biologics Development and Supply at Sobi
Sobi’s contract manufacturing of biologics provides a sustainable basis for research and development of the company’s new biologics – both financially and in terms of knowledge. Listen to Kirsti Gjellan on the future of highly specialized pharmaceutical manufacturing and how manufacturing knowledge is crucial for innovation in the field of biologics.
Christopher Siegmund, Site Manager for Pfizer’s Strägnäsfabrik
Pfizer is one of the world’s largest pharmaceutical companies and the company’s biotech manufacturing facility in Strängnäs is one of Northern Europe’s largest in the production of biopharmaceuticals. The company has continuously continued to invest in its Swedish facility, but where in the world the company chooses to place its production is continuously evaluated. Christopher Siegmund, site manager of the Strägnäs factory, explains the factors that determine where the factories end up.
Carl-Johan Sundberg, board member of Cobra Biologics, Professor KI
The virtual business culture that characterizes life sciences also affects manufacturing. Cobra Biologics is a Swedish company that specializes in helping smaller companies develop, scale up and manufacture advanced biologics. Listen to Carl-Johan Sundberg, board member of Cobra Biologics and professor at KI, talk about the role of the advanced contract manufacturer in increasing the value of Swedish companies and attracting foreign companies to Sweden.
The seminar and discussion will be led by Ingrid Heath, Vice President and Head of Policy at SwedenBIO.
